Clinical trials
Refractory Acute Lymphoblastic Leukemia clinical trials
Below are recruiting refractory acute lymphoblastic leukemia clinical trials, each written for real people, not researchers. We’re tracking 173 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05857969RecruitingPhase 1
Testing cancer drug response on removed tumor tissue
This early study uses tumor tissue (or bone marrow from blood cancers) and performs lab tests to see which cancer drugs may work better for each person. It also collects genetic information from blood or a saliva swab to help understand why cancers respond differently.
Miami, FloridaAges 1 day–21 years - NCT05495035RecruitingPhase 1
Olverembatinib plus APG-2575 for children with resistant leukemia
This study tests a new combination of two oral drugs (olverembatinib and APG-2575) for children with a type of leukemia (Ph+ ALL) that has returned or stopped responding to standard treatments. The goal is to see if this combination is safe and effective.
Hefei, AnhuiAges 1–18 - NCT04726241RecruitingPhase 1/Phase 2
Testing blood and bone marrow samples in young leukemia patients
This trial looks at blood and bone marrow samples from children and teens whose leukemia has come back or is hard to treat. The goal is to better understand the disease and guide future options for these patients.
Birmingham, AlabamaAges Up to 22 years - NCT07784309Enrolling by invitationPhase 1
Cell therapy for CD7-positive blood cancer
This study tests a new cell therapy for people with certain types of blood cancer that have returned or not responded to standard treatments. The therapy uses immune cells modified to target a marker called CD7 on cancer cells. It may help reduce or eliminate the cancer.
TianjinAges 3–70 - NCT07570173RecruitingPhase 2/Phase 3
MK-1045 for Hard-to-Treat B-Cell Leukemia
This trial tests a new drug called MK-1045 in patients whose acute lymphoblastic leukemia (a blood cancer) has come back or stopped responding to previous treatments. The goal is to see if this drug can help control the cancer when other options haven't worked.
Copenhagen, Capital RegionAges 12 years+ - NCT07070219RecruitingPhase 1/Phase 2
Study of CTD402 for T-cell leukemia or lymphoma
This trial tests a new drug called CTD402 for people with T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL) that has come back or not gone away after treatment. The goal is to see if CTD402 can help reduce or eliminate the cancer cells in the bone marrow.
Palo Alto, CaliforniaAges 1 year+ - NCT06137118RecruitingPhase 1/Phase 2
Study of AZD0486 for relapsed or refractory B-cell ALL
This trial tests a new investigational drug (AZD0486) given alone to see if it is safe and effective for people with B-cell acute lymphoblastic leukemia (ALL) that has come back or hasn't responded to treatment. It specifically targets a protein called CD19 found on leukemia cells.
Birmingham, AlabamaAges 12 years+ - NCT07565220RecruitingPhase 1
Thiotepa-based stem cell transplant for blood cancers
This trial tests a new chemotherapy preparation (using thiotepa) before a stem cell transplant from a matched donor to treat blood cancers like leukemia and myelodysplastic syndrome. The goal is to improve survival while reducing severe side effects.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06927466RecruitingPhase 1
B019 for relapsed or refractory B-cell acute lymphoblastic leukemia
This trial tests a new treatment called B019 for people whose B-cell acute lymphoblastic leukemia has come back or not responded to standard therapy. The treatment targets specific proteins on the cancer cells to help your immune system fight the leukemia.
BeijingAges 3–25 - NCT06533579RecruitingPhase 1/Phase 2
Gene therapy for CD19-positive blood cancers
This trial tests a new gene therapy treatment for people with certain types of leukemia or lymphoma that have the CD19 marker and have not responded to other treatments. The therapy uses a virus to deliver a gene to target and kill cancer cells.
Duarte, CaliforniaAges 13–90 - NCT07470073RecruitingEarly Phase 1
Universal CAR-T cell therapy for B-cell leukemia (ages 12-75)
This trial tests a new type of CAR-T cell therapy (called universal CAR-T) that targets CD19 and CD20 markers on cancer cells. It is for people aged 12 to 75 with B-cell acute lymphoblastic leukemia that has not responded to standard treatments or has come back after treatment.
Wuhan, HubeiAges 12–75 - NCT06376162RecruitingPhase 1
Ziftomenib with chemo for kids with relapsed acute leukemia
This trial tests a new targeted drug called ziftomenib combined with chemotherapy for children whose leukemia (with specific genetic changes) has come back or is not responding to treatment. The goal is to see if this combination can help control the cancer.
Los Angeles, CaliforniaAges birth–21 years - NCT07039877RecruitingPhase 2
Low-dose venetoclax with itraconazole and TACL for relapsed or refractory ALL
This trial tests a combination of low-dose venetoclax (a targeted cancer pill) plus itraconazole (an antifungal) and chemotherapy drugs for adults with acute lymphoblastic leukemia (ALL) that has come back or hasn't responded to first treatment.
Monterrey, Nuevo LeónAges 16–45 - NCT07371403Recruiting
Car-t cell therapy for relapsed or refractory acute lymphoblastic leukemia
This trial tests a type of immunotherapy called CAR-T cells that are made from your own blood cells and are designed to find and destroy leukemia cells. It is for patients whose leukemia has come back or hasn't gone away after other treatments.
AmmanAges 1 year+ - NCT03739814RecruitingPhase 2
Test inotuzumab, blinatumomab, and possibly ponatinib for CD22 ALL
This Phase 2 study tests a combination of medicines (inotuzumab ozogamicin and blinatumomab), with or without ponatinib, for people with CD22-positive B-cell acute lymphoblastic leukemia (ALL). It aims to improve remission and control leukemia cells, including in the bone marrow.
Birmingham, AlabamaAges 18 years+ - NCT06287944RecruitingPhase 1
Targeted radiation and chemo before donor stem cell transplant
This trial tests a new approach: giving a targeted radioactive antibody (attached to a drug that finds CD38 on cancer cells) along with low-dose chemotherapy and targeted radiation to the bone marrow before a donor stem cell transplant. The goal is to prepare the body for the transplant while killing remaining cancer cells more precisely.
Duarte, CaliforniaAges 18–70 - NCT07295951RecruitingPhase 1
Bleximenib Drug Study in Leukemia Patients
This study tests a radioactive form of the drug bleximenib in people with acute leukemia that has come back or not responded to treatment. It looks for specific genetic changes in the leukemia cells and may help researchers understand how the drug works in the body.
ManchesterAges 18 years+ - NCT07586618RecruitingPhase 1
New Drug 4A10 for Hard-to-Treat Lymphoblastic Leukemia or Lymphoma
This is an early-stage study testing a new experimental drug (4A10) in patients whose acute lymphoblastic leukemia or lymphoblastic lymphoma has returned or stopped responding to standard treatments. Researchers want to learn if the drug is safe and how it works in the body.
Aurora, ColoradoAges 18 years+ - NCT07387926RecruitingPhase 1/Phase 2
Testing asciminib for children and young adults with a type of leukemia
This trial tests an experimental drug called asciminib for children and young adults whose leukemia (a specific type of B-cell acute lymphoblastic leukemia with certain gene changes) has come back or not responded to treatment. The goal is to see if the drug is safe and effective for these patients.
Ramat GanAges 1–30 - NCT07532525RecruitingPhase 1
Pomalidomide after CAR T for B-cell cancer
This trial tests whether the drug pomalidomide, given as a pill, can help people with B-cell leukemia or lymphoma who have recently received CAR T-cell therapy. The goal is to see if pomalidomide can keep the cancer from coming back, and it may be an option for those whose cancer is not growing but still needs management.
Ann Arbor, MichiganAges 18 years+ - NCT03128034RecruitingPhase 1/Phase 2
Astatine-211 treatment before stem cell transplant for high-risk blood cancers
This trial tests a targeted radiation drug (Astatine-211) given before a donor stem cell transplant for people with high-risk leukemia or certain bone-marrow cancers. The goal is to better control the cancer before the transplant.
Seattle, WashingtonAges 18–75 - NCT03136146RecruitingPhase 2
Chemo for return or non-responsive blood cancers
This Phase 2 study tests a combination chemotherapy plan for certain leukemia and lymphoma types that have come back or did not respond. It may help shrink or control disease when standard treatment is no longer working.
Houston, TexasAges 15 years+ - NCT03326921RecruitingPhase 1
T cell treatment for leukemia after a bone marrow transplant
This early-phase trial tests an immune “T cell” therapy made to recognize a specific leukemia target. It is for people whose acute leukemia has come back (relapsed) or did not fully respond after receiving a donor stem cell transplant.
Seattle, WashingtonAges Up to 80 years - NCT03533816RecruitingPhase 1
Gamma delta T-cell infusion after stem cell transplant
This early-phase study tests giving a special immune-cell treatment after an allogeneic (donor) stem cell transplant, plus a medication given after transplant to help the new immune system work better. It may help prevent or treat cancer returning after transplant.
Westwood, KansasAges 18–65
Hear when a new Refractory Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Refractory Acute Lymphoblastic Leukemia trials by city
Studies with a site in or near these metro areas.
Refractory Acute Lymphoblastic Leukemia trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for refractory acute lymphoblastic leukemia?
- Yes. Clin2 currently lists 173 recruiting refractory acute lymphoblastic leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a refractory acute lymphoblastic leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a refractory acute lymphoblastic leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Refractory B Acute Lymphoblastic Leukemia
- Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
- T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
- Acute Lymphoblastic Leukemia
- Refractory Acute Myeloid Leukemia
- B-cell Acute Lymphoblastic Leukemia
- Relapsed/Refractory Acute Myeloid Leukemia
- T-cell Acute Lymphoblastic Leukemia
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.